[go: up one dir, main page]

PE20170777A1 - Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis - Google Patents

Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis

Info

Publication number
PE20170777A1
PE20170777A1 PE2017000424A PE2017000424A PE20170777A1 PE 20170777 A1 PE20170777 A1 PE 20170777A1 PE 2017000424 A PE2017000424 A PE 2017000424A PE 2017000424 A PE2017000424 A PE 2017000424A PE 20170777 A1 PE20170777 A1 PE 20170777A1
Authority
PE
Peru
Prior art keywords
apoptosis
solid oral
oral formulations
crystal forms
protein inhibitor
Prior art date
Application number
PE2017000424A
Other languages
English (en)
Inventor
Jeewan Thakur
Dong Yang
Lili Feng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20170777A1 publication Critical patent/PE20170777A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a una forma cristalina del hemi-hidrato HA de (S)-N-((S)-1-ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida de formula (I) que comprende un patron de difraccion en polvo de rayos-X que comprende valores 2 theta tales como 8,3; 9,5; 13,5; 17,3; 18,5 y 18,2 ± 0.2 a temperatura ambiente. Tambien se refiere a una composicion farmaceutica. Dicha forma cristalina es un inhibidor de las proteinas de apoptosis (IAPs), siendo util en el tratamiento del cancer
PE2017000424A 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis PE20170777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12

Publications (1)

Publication Number Publication Date
PE20170777A1 true PE20170777A1 (es) 2017-07-04

Family

ID=42937834

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000206A PE20121132A1 (es) 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis
PE2017000424A PE20170777A1 (es) 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000206A PE20121132A1 (es) 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis

Country Status (24)

Country Link
US (4) US8623385B2 (es)
EP (1) EP2464644A1 (es)
JP (3) JP2013501751A (es)
KR (2) KR20180020315A (es)
CN (2) CN105646471A (es)
AR (1) AR077869A1 (es)
AU (4) AU2010283748A1 (es)
BR (1) BR112012003118A2 (es)
CA (1) CA2769616A1 (es)
CL (1) CL2012000349A1 (es)
CO (1) CO6612189A2 (es)
IL (1) IL217760A0 (es)
IN (1) IN2012DN00858A (es)
MA (1) MA33511B1 (es)
MX (2) MX2012001844A (es)
MY (1) MY160475A (es)
PE (2) PE20121132A1 (es)
PH (1) PH12014501890B1 (es)
RU (1) RU2671196C1 (es)
SG (1) SG177713A1 (es)
TN (1) TN2012000026A1 (es)
TW (1) TWI607006B (es)
WO (1) WO2011018474A1 (es)
ZA (1) ZA201200390B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502861A (ja) * 2001-08-10 2005-01-27 サイミックス テクノロジーズ， インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
SG152225A1 (en) * 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
AU2017254950B2 (en) 2018-09-20
US20140093570A1 (en) 2014-04-03
RU2671196C1 (ru) 2018-10-30
CO6612189A2 (es) 2013-02-01
CA2769616A1 (en) 2011-02-17
AR077869A1 (es) 2011-09-28
PH12014501890A1 (en) 2015-09-14
RU2012108931A (ru) 2013-09-27
MX2012001844A (es) 2012-02-29
US9540363B2 (en) 2017-01-10
US20120128742A1 (en) 2012-05-24
AU2017254950A1 (en) 2017-11-23
MA33511B1 (fr) 2012-08-01
WO2011018474A1 (en) 2011-02-17
CN102471331B (zh) 2016-01-13
MX351274B (es) 2017-10-06
SG177713A1 (en) 2012-02-28
KR20180020315A (ko) 2018-02-27
IL217760A0 (en) 2012-03-29
CL2012000349A1 (es) 2012-09-07
US20180370960A1 (en) 2018-12-27
JP2013501751A (ja) 2013-01-17
US20170081319A1 (en) 2017-03-23
JP2018172403A (ja) 2018-11-08
CN105646471A (zh) 2016-06-08
ZA201200390B (en) 2012-10-31
JP2016179976A (ja) 2016-10-13
AU2010283748A1 (en) 2012-02-09
PE20121132A1 (es) 2012-09-04
CN102471331A (zh) 2012-05-23
BR112012003118A2 (pt) 2016-02-23
MY160475A (en) 2017-03-15
KR20120048008A (ko) 2012-05-14
PH12014501890B1 (en) 2015-09-14
US8623385B2 (en) 2014-01-07
TWI607006B (zh) 2017-12-01
TN2012000026A1 (en) 2013-09-19
TW201118091A (en) 2011-06-01
WO2011018474A8 (en) 2011-09-22
AU2014213533A1 (en) 2014-09-04
US10093665B2 (en) 2018-10-09
AU2016203145A1 (en) 2016-06-02
EP2464644A1 (en) 2012-06-20
IN2012DN00858A (es) 2015-07-10

Similar Documents

Publication Publication Date Title
PE20110217A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CY1117726T1 (el) Θετικοι αλλοστερικοι ρυθμιστες υποδοχεα μ1 κινολιναμιδιου
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CL2012001480A1 (es) Sal cristalina anhidra del acido monofosforico de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea, forma a y b; metodo de preparacion; composicion farmaceutica; y su uso en el tratamiento de carcinomas, psoriasis, entre otras.
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
DOP2011000135A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
CL2009001554A1 (es) Compuestos derivados de 4-(sulfonilaminoalquilamino)-n-fenil-n'-hidroxi-1,2,5-oxadiazol-3-carboximidamida; formas cristalinas; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades tales como cancer, infeccion viral, depresion, entre otras.
PE20081251A1 (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
BR112012015967A2 (pt) uso de compostos de fórmula geral (i) e composição farmacêutica
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
AR070018A1 (es) 5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il sulfamida, composiciones farmaceuticas que lo contienen, metodo de preparacion y uso del mismo en enfermedades asociadas al aumento de la vasoconstriccion, proliferacion o inflamacion debidas a endotelina, tales como insuficien
CL2015002606A1 (es) Compuesto.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
CL2013000756A1 (es) Forma cristalaina del citrato diacido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano; proceso de preparacion; composicion farmaceutica; y su uso para tratar o prevenir un trastorno de la memoria, un trastorno cognitivo, neurodegeneracion, entre otros.
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
PE20170777A1 (es) Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.

Legal Events

Date Code Title Description
FD Application declared void or lapsed